PRELUDE THERAPEUTICS INC Expense Breakdown
No Expense Breakdown for PRLD on this site yet.
- 2026-06-30: General Costs Including Personnel Related $11.54M; Jak2 V617f $2.27M; Kat6a $2.08M; Discovery Programs $229.00K.
- 2025-06-30: General Costs Including Personnel Related $15.69M; Jak2 V617f $1.88M; Kat6a $795.00K; Discovery Programs $612.00K.
Source checked: the stored Expense Breakdown page for PRLD.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | General Costs Including Personnel Related | Jak2 V617f | Kat6a | Discovery Programs | Other Research and Development |
|---|---|---|---|---|---|
| 2026-06-30 | $11.54M | $2.27M | $2.08M | $229.00K | $14.00K |
| 2025-06-30 | $15.69M | $1.88M | $795.00K | $612.00K | $6.80M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |